XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.25.3

Fair Value of Financial Instruments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Fair Value Disclosures [Abstract] |
Schedule of Investments Measured at Fair Value on Recurring Basis | Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2025 and December 31, 2024.
(in thousands) |  | Balance as of September 30, 2025 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Description |  |  |  |
Other assets and liabilities |  |  |  |  |  |  |  |
Escrow Receivables |  | $ | 145 |  |  | $ | — |  |  | $ | — |  |  | $ | 145 |
Accounts Payable and Accrued Liabilities |  | (34) |  |  | — |  |  | — |  |  | (34) |
Investments |  |  |  |  |  |  |  |
Senior Secured Debt |  | $ | 4,027,409 |  |  | $ | — |  |  | $ | — |  |  | $ | 4,027,409 |
Unsecured Debt |  | 68,149 |  |  | — |  |  | — |  |  | 68,149 |
Preferred Stock |  | 51,822 |  |  | — |  |  | — |  |  | 51,822 |
Common Stock(2) |  | 111,460 |  |  | 47,710 |  |  | — |  |  | 63,750 |
Warrants |  | 40,675 |  |  | — |  |  | 12,864 |  |  | 27,811 |
|  | $ | 4,299,515 |  |  | $ | 47,710 |  |  | $ | 12,864 |  |  | $ | 4,238,941 |
Investment Funds & Vehicles measured at Net Asset Value(3) |  | 6,639 |  |  |  |  |  |  |
Total Investments, at fair value |  | $ | 4,306,154 |  |  |  |  |  |  |
Derivative Instruments(4) |  | 86 |  |  |  |  |  |  |
Total Investments including cash and cash equivalents and derivative instruments |  | $ | 4,306,240 |  |  |  |  |  |  |
(in thousands) |  | Balance as of December 31, 2024 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Description |  |  |  |
Cash and cash equivalents |  |  |  |  |  |  |  |
Money Market Fund(1) |  | $ | 21,100 |  |  | $ | 21,100 |  |  | $ | — |  |  | $ | — |
Other assets and liabilities |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables |  | $ | 152 |  |  | $ | — |  |  | $ | — |  |  | $ | 152 |
Accounts Payable and Accrued Liabilities |  | (1,012) |  |  | $ | — |  |  | $ | — |  |  | (1,012) |
Investments |  |  |  |  |  |  |  |
Senior Secured Debt |  | $ | 3,419,044 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,419,044 |
Unsecured Debt |  | 75,557 |  |  | — |  |  | — |  |  | 75,557 |
Preferred Stock |  | 53,802 |  |  | — |  |  | — |  |  | 53,802 |
Common Stock(2) |  | 74,855 |  |  | 30,262 |  |  | — |  |  | 44,593 |
Warrants |  | 30,500 |  |  | — |  |  | 8,677 |  |  | 21,823 |
|  | $ | 3,653,758 |  |  | $ | 30,262 |  |  | $ | 8,677 |  |  | $ | 3,614,819 |
Investment Funds & Vehicles measured at Net Asset Value(3) |  | 6,220 |  |  |  |  |  |  |
Total Investments, at fair value |  | $ | 3,659,978 |  |  |  |  |  |  |
Derivative Instruments(4) |  | 538 |  |  |  |  |  |  |
Total Investments including cash and cash equivalents and derivative instruments |  | $ | 3,681,616 |  |  |  |  |  |  |
(1)This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities. (2)Common stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's common stock. (3)In accordance with U.S. GAAP, certain investments are measured at fair value using the NAV per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities. (4)Derivative Instruments are carried at fair value and are a Level 2 security within the Company's fair value hierarchy.
Schedule of Reconciliation Changes for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis | The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2025 and 2024.
(in thousands) | Balance as of January 1, 2025 |  | Net Realized Gains (Losses)(1) |  | Net Change in Unrealized Appreciation (Depreciation)(2) |  | Purchases(5) |  | Sales |  | Repayments(6) |  | Gross Transfers into Level 3(3)* |  | Gross Transfers out of Level 3(3)* |  | Balance as of September 30, 2025
Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior Secured Debt | $ | 3,419,044 |  |  | $ | (54,380) |  |  | $ | 42,790 |  |  | $ | 1,383,694 |  |  | $ | (67,521) |  |  | $ | (690,976) |  |  | $ | — |  |  | $ | (5,242) |  |  | $ | 4,027,409 |
Unsecured Debt | 75,557 |  |  | — |  |  | 547 |  |  | 4,267 |  |  | — |  |  | — |  |  | — |  |  | (12,222) |  |  | 68,149 |
Preferred Stock | 53,802 |  |  | — |  |  | (6,309) |  |  | 4,329 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 51,822 |
Common Stock | 44,593 |  |  | (645) |  |  | 2,969 |  |  | 975 |  |  | (1,606) |  |  | — |  |  | 22,558 |  |  | (5,094) |  |  | 63,750 |
Warrants | 21,823 |  |  | 607 |  |  | 1,419 |  |  | 5,372 |  |  | (1,410) |  |  | — |  |  | — |  |  | — |  |  | 27,811 |
Other Assets and Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow Receivables | 152 |  |  | 73 |  |  | (30) |  |  | 1,814 |  |  | (1,864) |  |  | — |  |  | — |  |  | — |  |  | 145 |
Accounts Payable and Accrued Liabilities | (1,012) |  |  | (568) |  |  | 1,534 |  |  | 2,003 |  |  | (1,991) |  |  | — |  |  | — |  |  | — |  |  | (34) |
Total | $ | 3,613,959 |  |  | $ | (54,913) |  |  | $ | 42,920 |  |  | $ | 1,402,454 |  |  | $ | (74,392) |  |  | $ | (690,976) |  |  | $ | 22,558 |  |  | $ | (22,558) |  |  | $ | 4,239,052 |
(in thousands) | Balance as of January 1, 2024 |  | Net Realized Gains (Losses)(1) |  | Net Change in Unrealized Appreciation (Depreciation)(2) |  | Purchases(5) |  | Sales |  | Repayments(6) |  | Gross Transfers into Level 3(4)* |  | Gross Transfers out of Level 3(4)* |  | Balance as of September 30, 2024
Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Senior Secured Debt | $ | 2,987,577 |  |  | $ | (9,120) |  |  | $ | (34,978) |  |  | $ | 1,099,563 |  |  | $ | — |  |  | $ | (732,225) |  |  | $ | — |  |  | $ | (4,093) |  |  | $ | 3,306,724 |
Unsecured Debt | 69,722 |  |  | — |  |  | 828 |  |  | 3,304 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 73,854 |
Preferred Stock | 53,038 |  |  | (711) |  |  | (9,013) |  |  | 1,597 |  |  | — |  |  | — |  |  | 2,431 |  |  | — |  |  | 47,342 |
Common Stock | 41,790 |  |  | (1,351) |  |  | 474 |  |  | 4,100 |  |  | — |  |  | — |  |  | 1,662 |  |  | — |  |  | 46,675 |
Warrants | 22,088 |  |  | (464) |  |  | (2,367) |  |  | 2,948 |  |  | (2,829) |  |  | — |  |  | — |  |  | — |  |  | 19,376 |
Other Assets and Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow and Other Investment Receivables | 10,888 |  |  | 85 |  |  | 5,869 |  |  | 43 |  |  | (18,497) |  |  | — |  |  | — |  |  | 1,770 |  |  | 158 |
Accounts Payable and Accrued Liabilities | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,770) |  |  | — |  |  | (1,770) |
Total | $ | 3,185,103 |  |  | $ | (11,561) |  |  | $ | (39,187) |  |  | $ | 1,111,555 |  |  | $ | (21,326) |  |  | $ | (732,225) |  |  | $ | 2,323 |  |  | $ | (2,323) |  |  | $ | 3,492,359 |
* The Company recognizes transfers as of the transaction date. (1)Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2)Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations. (3)During the three months ended March 31, 2025, 23andMe, Inc. Level 1 common stock was converted into Level 3 common stock due to bankruptcy and delisting. Subsequently, during the three months ended June 30, 2025, 23andMe, Inc. was treated as Level 1 common stock due to resumed trading after reaching a definitive agreement during the bankruptcy proceeding. Transfers out of Level 3 debt investments during the nine months ended September 30, 2025 related to the conversion of the Company's Level 3 debt investments in Hercules Adviser LLC, Carbon Health Technologies, Inc., and Khoros, LLC, into common stock Level 3 investments. (4)Transfers out of Level 3 during the nine months ended September 30, 2024 related to the conversion of the Company's Level 3 debt investments in Better Therapeutics, Inc. and Eigen Technologies Ltd. into common stock and preferred stock Level 3 investments in acquiring companies. (5)Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of Level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6)Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
Schedule of Unrealized Gain (Loss) on Investments | The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock and warrant Level 3 investments relating to assets still held at the reporting date.
(in millions) | Nine Months Ended September 30,
| 2025 |  | 2024
Debt investments | $ | 17.3 |  |  | $ | (32.3) |
Preferred stock | (6.3) |  |  | (9.2) |
Common stock | (2.5) |  |  | (0.3) |
Warrant investments | 1.6 |  |  | (0.8) |
Schedule of Quantitative Information of Fair Value Measurements | The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2025 and December 31, 2024. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation guidelines, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.
Investment Type - Level 3 Debt Investments |  | Fair Value as of September 30, 2025 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(2)
Pharmaceuticals |  | $ | 599,927 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 8.00% - 14.95% |  | 11.92%
|  |  |  |  | Premium/(Discount) |  | (2.50%) - 2.00% |  | 0.28%
Technology |  | 1,636,736 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.01% - 21.06% |  | 12.62%
|  |  |  |  | Premium/(Discount) |  | (1.50%) - 5.50% |  | 0.34%
|  | 29,770 |  |  | Convertible Note Analysis |  | Probability weighting of alternative outcomes |  | 1.00% - 70.00% |  | 51.07%
|  | 47,720 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 15.00% - 85.00% |  | 78.81%
Sustainable and Renewable Technology |  | 20,359 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 15.46% - 15.46% |  | 15.46%
|  |  |  |  | Premium/(Discount) |  | 1.00% - 1.00% |  | 1.00%
Medical Devices |  | 74,666 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 11.92% - 13.95% |  | 13.10%
|  |  |  |  |  | Premium/(Discount) |  | (0.25%) - 0.50% |  | 0.11%
Lower Middle Market |  | 669,245 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.02% - 18.45% |  | 13.96%
|  |  |  |  | Premium/(Discount) |  | 0.00% - 4.00% |  | 0.85%
Debt Investments for which Cost Approximates Fair Value
|  | 675,190 |  |  | Debt Investments originated within 6 months |  |  |  |
|  | 71,202 |  |  | Imminent Payoffs(4) |  |  |  |
|  | 232,737 |  |  | Debt Investments Maturing in Less than One Year |  |  |  |
|  | 38,006 |  |  | Debt Investments in Wholly-Owned Subsidiaries |  |  |  |
|  | $ | 4,095,558 |  |  | Total Level 3 Debt Investments |  |  |  |
Escrow Receivables |  | 145 |  |  | Expected Proceeds |  |  |  |  |  |
Accounts Payable and Accrued Liabilities |  | (34) |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 10.00% - 50.00% |  | 44.84%
|  | $ | 4,095,669 |  |  | Total Level 3 Debt Investments and Other Assets (Liabilities)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: •Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development”, “Biotechnology Tools” and “Healthcare Services, Other” industries. •Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, “Defense Technologies”, “Manufacturing Technology”, “Electronics & Computer Hardware” and “Software” industries. •Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. •Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry. •Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, “Consumer & Business Products” and “Software” industries. (2)The weighted averages are calculated based on the fair market value of each investment. (3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes. (4)Imminent Payoffs represent debt investments that the Company expects to be repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3 Debt Investments |  | Fair Value as of December 31, 2024 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(2)
Pharmaceuticals |  | $ | 947,065 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 8.42% - 16.19% |  | 12.03%
|  |  |  |  | Premium/(Discount) |  | (2.50%) - 3.00% |  | 0.13%
|  | 55,344 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 20.00% - 80.00% |  | 75.53%
Technology |  | 1,365,943 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.21% - 20.58% |  | 13.10%
|  |  |  |  | Premium/(Discount) |  | (0.75%) - 4.50% |  | 0.20%
|  | 26,869 |  |  | Convertible Note Analysis |  | Probability weighting of alternative outcomes |  | 1.00% - 70.00% |  | 50.66%
|  | 51,004 |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 22.00% - 78.00% |  | 66.34%
Sustainable and Renewable Technology |  | 21,102 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 12.41% - 15.44% |  | 15.25%
|  |  |  |  |  | Premium/(Discount) |  | 0.25% - 3.50% |  | 0.45%
Medical Devices |  | 59,645 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 11.79% - 12.75% |  | 12.24%
|  |  |  |  | Premium/(Discount) |  | 0.00% - 0.50% |  | 0.26%
Lower Middle Market |  | 636,258 |  |  | Market Comparable Companies |  | Hypothetical Market Yield |  | 10.27% - 21.00% |  | 14.12%
|  |  |  |  |  | Premium/(Discount) |  | (0.25%) - 5.00% |  | 1.07%
Debt Investments for which Cost Approximates Fair Value
|  | 242,833 |  |  | Debt Investments originated within 6 months |  |  |  |
|  | 4,141 |  |  | Imminent Payoffs(4) |  |  |  |
|  | 36,185 |  |  | Debt Investments Maturing in Less than One Year
|  | 48,212 |  |  | Debt Investments in Wholly-Owned Subsidiaries |  |  |  |
|  | $ | 3,494,601 |  |  | Total Level 3 Debt Investments
Accounts Payable and Accrued Liabilities |  | (1,012) |  |  | Liquidation(3) |  | Probability weighting of alternative outcomes |  | 20.00% - 50.00% |  | 38.44%
|  | $ | 3,493,589 |  |  | Total Level Three Debt Investments and Other Investment Receivables (Payables)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: •Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. •Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries. •Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. •Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry. •Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2)The weighted averages are calculated based on the fair market value of each investment. (3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes. (4)Imminent payoffs represent debt investments that the Company expects to be repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3 Equity and Warrant Investments |  | Fair Value as of September 30, 2025 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(5)
Equity Investments |  | $ | 46,346 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.2x - 16.1x |  | 7.4x
|  |  |  |  | Tangible Book Value Multiple(2) |  | 1.6x - 1.6x |  | 1.6x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 15.67% - 95.18% |  | 24.82%
|  | 9,934 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (88.34%) - 38.35% |  | (12.30%)
|  | 53,173 |  |  | Discounted Cash Flow |  | Discount Rate(7) |  | 11.29% - 34.19% |  | 29.69%
|  | 6,119 |  |  | Other(6) |  |  |  |  |  |
Warrant Investments |  | 21,289 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.6x - 14.5x |  | 4.4x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 15.65% - 33.10% |  | 26.43%
|  | 6,059 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (60.22%) - 46.76% |  | 10.84%
|  | 463 |  |  | Other(6) |  |  |  |  |  |
Total Level 3 Equity and Warrant Investments |  | $ | 143,383 |  |  |  |  |  |  |  |  |
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5)Weighted averages are calculated based on the fair market value of each investment. (6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Investment Type - Level 3 Equity and Warrant Investments |  | Fair Value as of December 31, 2024 (in thousands) |  | Valuation Techniques/ Methodologies |  | Unobservable Input(1) |  | Range |  | Weighted Average(5)
Equity Investments |  | $ | 45,420 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.4x - 16.8x |  | 9.1x
|  |  |  |  | Tangible Book Value Multiple(2) |  | 1.7x - 1.7x |  | 1.7x
|  |  |  |  | Discount for Lack of Marketability(3) |  | 17.64% - 92.80% |  | 36.12%
|  | 12,374 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (96.57%) - 24.76% |  | (17.57%)
|  | 34,677 |  |  | Discounted Cash Flow |  | Discount Rate(7) |  | 12.17% - 33.34% |  | 30.21%
|  | 5,924 |  |  | Other(6) |  |  |  |  |  |
Warrant Investments |  | 18,302 |  |  | Market Comparable Companies |  | Revenue Multiple(2) |  | 0.8x - 14.1x |  | 4.5x
|  |  |  |  |  | Discount for Lack of Marketability(3) |  | 14.72% - 34.35% |  | 26.76%
|  | 3,521 |  |  | Market Adjusted OPM Backsolve |  | Market Equity Adjustment(4) |  | (56.36%) - 24.76% |  | 1.33%
Total Level 3 Equity and Warrant Investments |  | $ | 120,218 |  |  |  |  |  |  |  |  |
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5)Weighted averages are calculated based on the fair market value of each investment. (6)The fair market value of these investments is derived based on recent market transactions. (7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Schedule of Fair Value Hierarchy of Outstanding Borrowings | The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2025 and December 31, 2024:
(in thousands) |  | September 30, 2025
Description |  | Carrying Value |  | Approximate Fair Value |  | Identical Assets (Level 1) |  | Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
SBA Debentures |  | $ | 340,717 |  |  | $ | 331,845 |  |  | $ | — |  |  | $ | — |  |  | $ | 331,845 |
March 2026 A Notes |  | 49,961 |  |  | 49,958 |  |  | — |  |  | — |  |  | 49,958 |
March 2026 B Notes |  | 49,957 |  |  | 49,970 |  |  | — |  |  | — |  |  | 49,970 |
September 2026 Notes |  | 324,057 |  |  | 316,646 |  |  | — |  |  | — |  |  | 316,646 |
January 2027 Notes |  | 348,263 |  |  | 342,948 |  |  | — |  |  | — |  |  | 342,948 |
2028 Convertible Notes |  | 279,747 |  |  | 286,121 |  |  | — |  |  | 286,121 |  |  | — |
June 2030 Notes |  | 342,219 |  |  | 362,985 |  |  | — |  |  | — |  |  | 362,985 |
2031 Asset-Backed Notes |  | 88,391 |  |  | 86,937 |  |  | — |  |  | 86,937 |  |  | — |
2033 Notes |  | 39,124 |  |  | 40,432 |  |  | — |  |  | 40,432 |  |  | — |
MUFG Bank Facility |  | 66,000 |  |  | 66,000 |  |  | — |  |  | — |  |  | 66,000 |
SMBC Facility |  | 222,702 |  |  | 222,866 |  |  | — |  |  | — |  |  | 222,866 |
Total |  | $ | 2,151,138 |  |  | $ | 2,156,708 |  |  | $ | — |  |  | $ | 413,490 |  |  | $ | 1,743,218 |
(in thousands) |  | December 31, 2024
Description |  | Carrying Value |  | Approximate Fair Value |  | Identical Assets (Level 1) |  | Observable Inputs (Level 2) |  | Unobservable Inputs (Level 3)
SBA Debentures |  | $ | 271,371 |  |  | $ | 260,436 |  |  | $ | — |  |  | $ | — |  |  | $ | 260,436 |
February 2025 Notes |  | 49,981 |  |  | 50,698 |  |  | — |  |  | — |  |  | 50,698 |
June 2025 Notes |  | 69,919 |  |  | 69,308 |  |  | — |  |  | — |  |  | 69,308 |
June 2025 3-Year Notes |  | 49,926 |  |  | 49,713 |  |  | — |  |  | — |  |  | 49,713 |
March 2026 A Notes |  | 49,889 |  |  | 49,052 |  |  | — |  |  | — |  |  | 49,052 |
March 2026 B Notes |  | 49,880 |  |  | 49,087 |  |  | — |  |  | — |  |  | 49,087 |
September 2026 Notes |  | 323,321 |  |  | 302,244 |  |  | — |  |  | — |  |  | 302,244 |
January 2027 Notes |  | 347,265 |  |  | 327,928 |  |  | — |  |  | — |  |  | 327,928 |
2031 Asset-Backed Notes |  | 118,769 |  |  | 115,031 |  |  | — |  |  | 115,031 |  |  | — |
2033 Notes |  | 39,043 |  |  | 40,272 |  |  | — |  |  | 40,272 |  |  | — |
MUFG Bank Facility |  | 116,000 |  |  | 116,000 |  |  | — |  |  | — |  |  | 116,000 |
SMBC Facility |  | 283,591 |  |  | 283,591 |  |  | — |  |  | — |  |  | 283,591 |
Total |  | $ | 1,768,955 |  |  | $ | 1,713,360 |  |  | $ | — |  |  | $ | 155,303 |  |  | $ | 1,558,057 |

X
- Definition Summary of reconciliation changes for financial assets and liabilities measured at fair value on recurring basis. + References No definition available. + Details
Name: | htgc_SummaryOfReconciliationChangesForFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisTableTextBlock
Namespace Prefix: | htgc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information about fair value of asset and liability not measured at fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E + Details
Name: | us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of unrealized gains and losses on investments. + References No definition available. + Details
Name: | us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration